Morgan Stanley Cuts Alnylam Price Target to $240, Keeps Equal-Weight
Morgan Stanley lowered its price target on Alnylam Pharmaceuticals to $240 from $300 while maintaining its Equal-Weight rating.
Related stories
Twilio Shares Fall 17.26% Despite Nearly 24% Free-Cash-Flow Margin
Twilio fell 17.25% to $200.16 on October 30. Its growth outlook overshadowed strong cash generation, the report says.
M impact | EQUITY | Oct 30, 2026, 07:32 PM UTC
AMD Shares Fell Nearly 10% Friday as Chip Demand Concerns Grew
AMD shares dropped nearly 10% in Friday morning trading as investors questioned whether chip-industry demand could hold up after a rival’s disappointing outlook. AMD is scheduled t
M impact | EQUITY | Oct 30, 2026, 07:31 PM UTC
US session market picture: S&P 500 -2.13%, Nasdaq 100 -3.87%; EUR/USD -0.09%, WTI +1.43%, INTC leads volume
US session market picture. US index futures: S and P futures is down 2.13 percent, Nasdaq futures is down 3.87 percent, Dow futures is down 1.32 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 07:30 PM UTC
Alphabet Convertible Preferred Yield Tops 7.5%
Alphabet’s mandatory convertible preferred stock, issued as part of its $85 billion equity capital-raising plan in June, has fallen alongside the company’s common stock and now yie
H impact | EQUITY | Oct 30, 2026, 07:25 PM UTC
JioStar Q2 Profit Falls 13% Amid Weak Advertising Environment
Reliance Industries' entertainment subsidiary reported September-quarter revenue up 10% year on year to Rs. 6,806 crore and EBITDA down nearly 14% to Rs. 1,502 crore. Profit after
M impact | EQUITY | Oct 30, 2026, 07:18 PM UTC
Nasdaq Near Session Lows Approaching Close
The Nasdaq remained near session lows approaching the close.
M impact | EQUITY | Oct 30, 2026, 07:16 PM UTC